Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
Averna Therapeutics named one of Endpoints News 2025 Winners of the Endpoints 11 Awards, Highlighting Biotech’s Most Promising Startups
Rgenta Therapeutics Receives Orphan Drug Designation from the U.S. FDA for RGT-61159 for the Treatment of Adenoid Cystic Carcinoma (ACC)
Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy
Imperative Care Announces FDA Clearance of Symphony Thrombectomy System, the First Large-Bore Continuous Vacuum System for Treatment of Pulmonary Embolism
